SCHEMBL2948173

SCHEMBL2948173

CCCCCCCCCCOc1ccc(C=O)cc1OCCCCCCCCCC

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.63
MAPT P10636 9/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPSR1 Q6W5P4 3/20 0.55
LMNA P02545 3/20 0.55
HTT P42858 2/20 0.55
ALDH1A1 P00352 12/20 0.53
HPGD P15428 7/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
TACR2 P21452 1/20 0.50
CYP2C9 P11712 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
TSHR P16473 1/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
HSP90AA1 P07900 1/20 0.48
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30317585 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL30317632 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL2945520 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL10497454 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL30317637 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL8373569 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL10497561 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL10497979 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL5053914 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA
SCHEMBL2941799 1.00 FDPS (0.63) FDPSMAPTSMN1; SMN2NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2460855-A2 Oxygen scavenging compositions and packaging comprising said compositions Constar International Inc. (US) 2012-06-06 EP claimed
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions CONSTAR INTERNATIONAL, INC (US) 2009-11-12 US claimed
EP-1848659-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS Constar International Inc. (US) 2007-10-31 EP claimed
WO-2006088889-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INTERNATIONAL, INC. (US) 2006-08-24 WO claimed
US-20060180790-A1 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2006-08-17 US claimed
US-8721920-B2 Oxygen scavenging compositions and packaging comprising said compositions PLASTIPAK PACKAGING, INC. (US) 2014-05-13 US disclosed
EP-1848659-B1 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INT INC (US) 2013-03-20 EP disclosed
EP-2460855-A2 Oxygen scavenging compositions and packaging comprising said compositions Constar International Inc. (US) 2012-06-06 EP disclosed
US-20100154361-A1 Oxygen Scavenging Compositions And Packaging Comprising Said Compositions CONSTAR INTERNATIONAL, INC. (US) 2010-06-24 US disclosed
US-7691290-B2 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2010-04-06 US disclosed
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions CONSTAR INTERNATIONAL, INC (US) 2009-11-12 US disclosed
EP-1848659-A4 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INT INC (US) 2009-08-12 EP disclosed
US-20060180790-A1 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2006-08-17 US disclosed
EP-0664282-B1 Biaryl phospholipase A2 inhibitors BRISTOL MYERS SQUIBB CO (US) 1997-10-22 EP disclosed
EP-0629604-B1 Alicyclic phospholipase A2 inhibitors BRISTOL MYERS SQUIBB CO (US) 1997-04-16 EP disclosed
EP-0664282-A1 Biaryl phospholipase A2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-26 EP disclosed
US-5436369-A Alicyclic phospholipase A2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-25 US disclosed
US-5391817-A Antiinflammatory agents BRISTOL-MYERS SQUIBB (US) 1995-02-21 US disclosed
EP-0629604-A2 Alicyclic phospholipase A2 inhibitors Bristol-Myers Company (US) 1994-12-21 EP disclosed
EP-0328669-A1 CHALCONE DERIVATIVE COMPOUNDS NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1989-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions LPO, GPX4, PRDX3 FDPS 3879/4885MAPT 3540/4885SMN1; SMN2 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.